Inventor · Sudbury, MA, US

Clark Pan

54Patents
13h-index
82Co-inventors
87Inventor score

Filing activity: Jun 14, 1996 → Mar 2, 2023

Most-cited inventions

PatentTitleAreaCited byStatus
US7091323B2 Human TIMP-1 antibodies Chemistry; Metallurgy 43 Expired
US6391607B1 Human DNase I hyperactive variants Human Necessities 37 Expired
US7632921B2 Site-directed modification of FVIII Chemistry; Metallurgy 35 Expired
US7041646B2 Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists Human Necessities 33 Expired
US9790268B2 Fc containing polypeptides with altered glycosylation and reduced effector function Chemistry; Metallurgy 20 Active
US7785580B2 Modified IL-4 mutein receptor antagonists Human Necessities 16 Active
US7407785B2 Human DNase I hyperactive variants Human Necessities 16 Expired
US6972319B1 Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use Human Necessities 16 Expired
US7507714B2 Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use Human Necessities 15 Expired
US6864069B2 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use Human Necessities 15 Expired
US7432364B2 Human TIMP-1 antibodies Chemistry; Metallurgy 15 Active
US9701753B2 Hyperglycosylated binding polypeptides Chemistry; Metallurgy 13 Active
US9580511B2 Site-specific antibody-drug conjugation through glycoengineering Chemistry; Metallurgy 13 Active
US10836813B2 Fc containing polypeptides with altered glycosylation and reduced effector function Chemistry; Metallurgy 9 Active
US7378494B2 Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonist peptide Human Necessities 8 Expired
US8835614B2 Oligosaccharide-protein conjugates Human Necessities 8 Active
US10214589B2 Site-specific antibody-drug conjugation through glycoengineering Chemistry; Metallurgy 7 Active
US11186638B2 Anti-αβTCR antibody Chemistry; Metallurgy 7 Active
US10494439B2 Hyperglycosylated binding polypeptides Chemistry; Metallurgy 6 Active
US9493498B2 Oligosaccharide-protein conjugates Human Necessities 6 Active
US10017573B2 Anti-αβTCR antibody Chemistry; Metallurgy 6 Active
US10995148B2 Site-specific glycoengineering of targeting moieties Chemistry; Metallurgy 6 Active
US10308917B2 Nucleotide sequences encoding VEGF antagonist compositions of FLT-1 and uses thereof Chemistry; Metallurgy 5 Active
US9441029B2 VEGF antagonist compositions and uses thereof Chemistry; Metallurgy 5 Active
US10464962B2 Oligosaccharide-protein conjugates Human Necessities 5 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.